Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
Terminated
University of Zurich
Phase 4
2004-10-01
The randomized, double-blind, placebo-controlled study aim to evaluate the effect of 1-month
therapy with folic acid (5 mg/day) on endothelial function and baroreceptor function in
patients with heart failure.
Endothelial function will be studied non-invasively with flow-mediated dilation while for
eveluating baroreceptor function sympathetic nervous system activity will be measured
directly with microneurography in baseline condition and during infusion of
sodium-nitroprusside.
Treatment of Suspected Cholelithiasis With Nitroglycerin
Unknown status
United States Naval Medical Center, San Diego
Phase 2
2014-10-01
ABSTRACT: Sublingual nitroglycerin has been advocated for the treatment of acute pain from
suspected symptomatic cholelithiasis. There is, however, no clinical studies that validate
its use. This study is designed to evaluate the efficacy of nitroglycerine in relieving acute
pain of suspected biliary tract origin.
Nitroglycerin is a potent smooth muscle relaxant used for biliary tract dilation during ERCP,
(Chelly, J) and has been recommended for treatment of biliary colic based on anecdotal
experience and small case reports. Nitroglycerin effect is a result of the nitric oxide
component of the medication which acts as a smooth muscle relaxant in vascular, bronchial,
esophageal and biliary smooth muscles. [McGowan(1936), Chelly (1979),Toyoyama (2001)] The
typical dose of nitroglycerin is 0.4 mg given sublingually in pill form or, more recently, in
a metered spray form. In a case series reported by Hassel (1993), positive response times
ranged from 20 to 60 seconds with duration of action of two to twelve hours. Sublingual
nitroglycerin is most commonly used for treatment of chest pain related to insufficient
cardiac perfusion. It has also been noted to relieve the pain of esophageal spasms.
Nitroglycerin has an excellent safety profile if used in patients with adequate pretreatment
blood pressures. [Newberry (2005), Nitroglycerine (2011), Nitro (2011), Wolters (2009)] This
study proposes to compare sublingual 0.4 mg doses of nitroglycerin to placebo for the initial
treatment of acute pain from suspected symptomatic cholelithiasis
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
